MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.89
+0.61
+6.57%
After Hours: 9.89 0 0.00% 16:00 09/25 EDT
OPEN
9.30
PREV CLOSE
9.28
HIGH
9.93
LOW
9.10
VOLUME
254.10K
TURNOVER
--
52 WEEK HIGH
15.82
52 WEEK LOW
4.550
MARKET CAP
289.21M
P/E (TTM)
-3.6911
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eiger: Upcoming Catalysts And Platform Make It A Buy
Short-term catalyst is the near-certain approval of lonafarnib in HGPS.No commercial value in HGPS, but lonafarnib MoA sets stage for fast tracking HDV candidate.Our semi automated TPT scoring system gives a score of above 70, making EIGR a buy.
Seekingalpha · 2d ago
Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock Options
Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.
Zacks · 09/15 13:54
Billionaire David Shaw Pours Money Into 3 Strong Buy Stocks
Are the tides turning on Wall Street? Stocks fell for a third consecutive session, as investors abandoned the tech heavyweights that have been at the forefront of the market’s remarkable charge forward. What’s behind the sell-off? Sky-high valuations reminiscent of the dot-com era have sparked fears
TipRanks · 09/09 14:36
Eiger Bio to Participate in September 2020 Investor Conferences
PR Newswire · 09/01 13:00
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress 2020
PR Newswire · 08/31 13:00
Eiger Announces Peginterferon Lambda-Lonafarnib Combination End Of Treatment Results From Phase 2 LIFT HDV Study At Digital International Liver Congress 2020
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020 PALO ALTO,
Benzinga · 08/31 12:27
Enanta Pharma reports encouraging data on HBV and NASH candidates
Data from Enanta Pharmaceuticals' (ENTA) development programs for non-alcoholic steatohepatitis ((NASH)) and hepatitis B virus ((HBV)) will be virtually presented at the European Association for the Study of the Liver Annual
Seekingalpha · 08/28 11:59
The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 12:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EIGR. Analyze the recent business situations of Eiger through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EIGR stock price target is 34.17 with a high estimate of 55.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 22.24M
% Owned: 76.07%
Shares Outstanding: 29.24M
TypeInstitutionsShares
Increased
46
2.15M
New
35
-126.91K
Decreased
17
451.78K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.18%
Pharmaceuticals & Medical Research
+1.35%
Key Executives
Chairman/Independent Director
Thomas Dietz
President/Chief Executive Officer/Director
David Cory
Chief Financial Officer
Sriram Ryali
Executive Vice President
Eldon Mayer
Chief Compliance Officer/General Counsel/Secretary
Stephana Patton
Other
James Shaffer
Director
David Apelian
Independent Director
Jeffrey Glenn
Independent Director
Evan Loh
Independent Director
Christine Murray
Independent Director
Amit Sachdev
Director
Patrick Y. Yang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EIGR
Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.